NCT07131293 European Registry Study on Lymphatic Interventions
| NCT ID | NCT07131293 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Lymphatic Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2030-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2026-02-01 with a primary completion date of 2030-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This European multicenter observational study aims to evaluate the real-world use, timing, and outcomes of lymphatic interventions in patients with congenital heart disease and/or primary lymphatic disorders. The study will examine the effectiveness of diagnostic imaging and interventional techniques, such as lymphatic embolization, in improving clinical symptoms, biomarkers, and fluid-related complications. The central question is whether early diagnosis and targeted intervention can lead to clinically meaningful improvements and reduced need for reintervention. Data collected retrospectively and prospectively from participating centers will help identify predictors of outcome, assess disease severity, and inform standardized diagnostic and therapeutic pathways across Europe.
Eligibility Criteria
Inclusion Criteria: * Patients of any age with a confirmed central lymphatic disorder, either in the context of CHD or as a primary lymphatic disorder, verified through lymphatic diagnostics (e.g. lymphatic imaging or relevant biomarkers). * Patients who have undergone, or are undergoing, diagnostic lymphatic imaging and/or interventional procedures for their lymphatic disorder. * Patients who are receiving, or have received, conservative (non-interventional) management for their lymphatic disorder. Exclusion Criteria: * Patients with isolated peripheral lymphatic disorders not involving the central lymphatic system. * Patients with acute postoperative iatrogenic chylothorax (\<3-4 weeks duration and not requiring intervention). * Patients without sufficient clinical documentation to confirm diagnosis, treatment, or follow-up. * Patients who decline, or whose legal guardians decline, to provide informed consent (for prospective inclusion).
Contact & Investigator
Vibeke E Hjortdal, Professor
STUDY DIRECTOR
Rigshospitalet, Denmark
Frequently Asked Questions
Who can join the NCT07131293 clinical trial?
This trial is open to participants of all sexes, studying Lymphatic Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07131293 currently recruiting?
Yes, NCT07131293 is actively recruiting participants. Contact the research team at sanam.safi-rasmussen@regionh.dk for enrollment information.
Where is the NCT07131293 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT07131293 clinical trial?
NCT07131293 is sponsored by Rigshospitalet, Denmark. The principal investigator is Vibeke E Hjortdal, Professor at Rigshospitalet, Denmark. The trial plans to enroll 500 participants.